Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca

AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.